This report examines workforce diversity across the pharmaceutical and biotechnology industries, highlighting persistent representation gaps and their impact on innovation and patient care. Data from MassBio, the U.S. Bureau of Labor Statistics, and BIO show that while nearly half of pharma employees are women, people of color remain underrepresented—especially in leadership roles. The analysis underscores how limited diversity in clinical trials and corporate teams can lead to inequities in treatment outcomes. It also points to growing industry recognition of inclusion as a strategic priority, with most biotech companies now tracking workforce demographics to drive accountability and equity.
Topics
DEI Strategy and Measurement
